Cargando…

Changes in Gut Microbiota and Metabolites in Papillary Thyroid Carcinoma Patients Following Radioactive Iodine Therapy

PURPOSE: Radioactive iodine therapy is administered through oral route, which is accumulated and absorbed in the intestine. However, its effects on the intestine remain unclear. In this study, we investigated the changes in the gut microbiota and metabolites following radioactive iodine therapy. PAT...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wanting, Cheng, Feng, Zhang, Jun, Li, Caihong, Yu, Daijing, Simayijiang, Halimureti, Liu, Haiyan, Li, Sijin, Yan, Jiangwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557971/
https://www.ncbi.nlm.nih.gov/pubmed/37808207
http://dx.doi.org/10.2147/IJGM.S433433
_version_ 1785117185853620224
author Li, Wanting
Cheng, Feng
Zhang, Jun
Li, Caihong
Yu, Daijing
Simayijiang, Halimureti
Liu, Haiyan
Li, Sijin
Yan, Jiangwei
author_facet Li, Wanting
Cheng, Feng
Zhang, Jun
Li, Caihong
Yu, Daijing
Simayijiang, Halimureti
Liu, Haiyan
Li, Sijin
Yan, Jiangwei
author_sort Li, Wanting
collection PubMed
description PURPOSE: Radioactive iodine therapy is administered through oral route, which is accumulated and absorbed in the intestine. However, its effects on the intestine remain unclear. In this study, we investigated the changes in the gut microbiota and metabolites following radioactive iodine therapy. PATIENTS AND METHODS: A total of 76 stool samples from the same 38 patients were collected at the start of radioactive iodine therapy and three days following the therapy. Stool microbiota and metabolites were detected using 16S rRNA gene sequencing and liquid chromatography-mass spectrometry. RESULTS: Enterobacteriales, Enterobacteriaceae and Escherichia-Shigella were elevated in most patients (27/38) following the therapy. The levels of 2-hydroxyundec-7-enoylcarnitine were significantly lower, whereas those of 5-dehydroavenasterol, butylisopropylamine, and salsoline-1-carboxylate were higher following the therapy. The relative abundance of Escherichia-Shigella was negatively correlated with 2-hydroxyundec-7-enoylcarnitine level (r(2) = −0.661, P = 0.009). Functional pathways were predicted to be involved in amino acid and lipid metabolism following the therapy. Particularly, phenylalanine, linoleic acid, sphingolipid, purine, and alpha-linolenic acid metabolism were the main metabolic pathways. CONCLUSION: Gut microbiota was disturbed following radioactive iodine therapy, with increased Escherichia-Shigella. Processes associated with energy production seems to be impacted following the therapy, with significantly decreased 2-hydroxyundec-7-enoylcarnitine level. Meanwhile, some metabolites and functional pathways may have a positive effect on intestinal homeostasis, and may be related to the repair and promotion of gut recovery following the therapy. This study provides a basic foundation to explore how radioactive iodine affects gut microbiota and metabolites, and how gut function is regulated in response to radioactive iodine therapy.
format Online
Article
Text
id pubmed-10557971
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105579712023-10-07 Changes in Gut Microbiota and Metabolites in Papillary Thyroid Carcinoma Patients Following Radioactive Iodine Therapy Li, Wanting Cheng, Feng Zhang, Jun Li, Caihong Yu, Daijing Simayijiang, Halimureti Liu, Haiyan Li, Sijin Yan, Jiangwei Int J Gen Med Original Research PURPOSE: Radioactive iodine therapy is administered through oral route, which is accumulated and absorbed in the intestine. However, its effects on the intestine remain unclear. In this study, we investigated the changes in the gut microbiota and metabolites following radioactive iodine therapy. PATIENTS AND METHODS: A total of 76 stool samples from the same 38 patients were collected at the start of radioactive iodine therapy and three days following the therapy. Stool microbiota and metabolites were detected using 16S rRNA gene sequencing and liquid chromatography-mass spectrometry. RESULTS: Enterobacteriales, Enterobacteriaceae and Escherichia-Shigella were elevated in most patients (27/38) following the therapy. The levels of 2-hydroxyundec-7-enoylcarnitine were significantly lower, whereas those of 5-dehydroavenasterol, butylisopropylamine, and salsoline-1-carboxylate were higher following the therapy. The relative abundance of Escherichia-Shigella was negatively correlated with 2-hydroxyundec-7-enoylcarnitine level (r(2) = −0.661, P = 0.009). Functional pathways were predicted to be involved in amino acid and lipid metabolism following the therapy. Particularly, phenylalanine, linoleic acid, sphingolipid, purine, and alpha-linolenic acid metabolism were the main metabolic pathways. CONCLUSION: Gut microbiota was disturbed following radioactive iodine therapy, with increased Escherichia-Shigella. Processes associated with energy production seems to be impacted following the therapy, with significantly decreased 2-hydroxyundec-7-enoylcarnitine level. Meanwhile, some metabolites and functional pathways may have a positive effect on intestinal homeostasis, and may be related to the repair and promotion of gut recovery following the therapy. This study provides a basic foundation to explore how radioactive iodine affects gut microbiota and metabolites, and how gut function is regulated in response to radioactive iodine therapy. Dove 2023-10-02 /pmc/articles/PMC10557971/ /pubmed/37808207 http://dx.doi.org/10.2147/IJGM.S433433 Text en © 2023 Li et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Li, Wanting
Cheng, Feng
Zhang, Jun
Li, Caihong
Yu, Daijing
Simayijiang, Halimureti
Liu, Haiyan
Li, Sijin
Yan, Jiangwei
Changes in Gut Microbiota and Metabolites in Papillary Thyroid Carcinoma Patients Following Radioactive Iodine Therapy
title Changes in Gut Microbiota and Metabolites in Papillary Thyroid Carcinoma Patients Following Radioactive Iodine Therapy
title_full Changes in Gut Microbiota and Metabolites in Papillary Thyroid Carcinoma Patients Following Radioactive Iodine Therapy
title_fullStr Changes in Gut Microbiota and Metabolites in Papillary Thyroid Carcinoma Patients Following Radioactive Iodine Therapy
title_full_unstemmed Changes in Gut Microbiota and Metabolites in Papillary Thyroid Carcinoma Patients Following Radioactive Iodine Therapy
title_short Changes in Gut Microbiota and Metabolites in Papillary Thyroid Carcinoma Patients Following Radioactive Iodine Therapy
title_sort changes in gut microbiota and metabolites in papillary thyroid carcinoma patients following radioactive iodine therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557971/
https://www.ncbi.nlm.nih.gov/pubmed/37808207
http://dx.doi.org/10.2147/IJGM.S433433
work_keys_str_mv AT liwanting changesingutmicrobiotaandmetabolitesinpapillarythyroidcarcinomapatientsfollowingradioactiveiodinetherapy
AT chengfeng changesingutmicrobiotaandmetabolitesinpapillarythyroidcarcinomapatientsfollowingradioactiveiodinetherapy
AT zhangjun changesingutmicrobiotaandmetabolitesinpapillarythyroidcarcinomapatientsfollowingradioactiveiodinetherapy
AT licaihong changesingutmicrobiotaandmetabolitesinpapillarythyroidcarcinomapatientsfollowingradioactiveiodinetherapy
AT yudaijing changesingutmicrobiotaandmetabolitesinpapillarythyroidcarcinomapatientsfollowingradioactiveiodinetherapy
AT simayijianghalimureti changesingutmicrobiotaandmetabolitesinpapillarythyroidcarcinomapatientsfollowingradioactiveiodinetherapy
AT liuhaiyan changesingutmicrobiotaandmetabolitesinpapillarythyroidcarcinomapatientsfollowingradioactiveiodinetherapy
AT lisijin changesingutmicrobiotaandmetabolitesinpapillarythyroidcarcinomapatientsfollowingradioactiveiodinetherapy
AT yanjiangwei changesingutmicrobiotaandmetabolitesinpapillarythyroidcarcinomapatientsfollowingradioactiveiodinetherapy